UBS Group’s Genetic Technologies Ltd. GENE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q4 | – | Sell |
-8,866
| Closed | -$6.87K | – | 10771 |
|
|
2024
Q3 | $6.87K | Buy |
+8,866
| New | +$7.88K | ﹤0.01% | 7950 |
|
|
2024
Q2 | – | Sell |
-219
| Closed | -$633 | – | 10383 |
|
|
2024
Q1 | $633 | Sell |
219
-2,775
| -93% | -$6.38K | ﹤0.01% | 8433 |
|
|
2023
Q4 | $7.19K | Buy |
+2,994
| New | +$9.93K | ﹤0.01% | 7641 |
|
|
2023
Q3 | – | Sell |
-20
| Closed | -$83 | – | 10160 |
|
|
2023
Q2 | $83 | Sell |
20
-710
| -97% | -$3.52K | ﹤0.01% | 8538 |
|
|
2023
Q1 | $4.24K | Sell |
730
-749
| -51% | -$4.38K | ﹤0.01% | 8214 |
|
|
2022
Q4 | $6.88K | Buy |
1,479
+805
| +119% | +$4.56K | ﹤0.01% | 8974 |
|
|
2022
Q3 | $4K | Sell |
674
-685
| -50% | -$5K | ﹤0.01% | 9434 |
|
|
2022
Q2 | $8K | Buy |
1,359
+347
| +34% | +$2.51K | ﹤0.01% | 8385 |
|
|
2022
Q1 | $10K | Buy |
1,012
+77
| +8% | +$748 | ﹤0.01% | 8461 |
|
|
2021
Q4 | $9K | Buy |
935
+920
| +6,133% | +$11.8K | ﹤0.01% | 8955 |
|
|
2021
Q3 | $0 | Sell |
15
-682
| -98% | -$11.7K | ﹤0.01% | 10267 |
|
|
2021
Q2 | $14K | Buy |
697
+498
| +250% | +$10K | ﹤0.01% | 7729 |
|
|
2021
Q1 | $4K | Sell |
199
-367
| -65% | -$8.4K | ﹤0.01% | 8446 |
|
|
2020
Q4 | $10K | Buy |
566
+551
| +3,673% | +$9.1K | ﹤0.01% | 7512 |
|
|
2020
Q3 | $0 | Sell |
15
-1,203
| -99% | -$22.4K | ﹤0.01% | 8523 |
|
|
2020
Q2 | $14K | Buy |
1,218
+1,203
| +8,020% | +$12.3K | ﹤0.01% | 6803 |
|
|
2020
Q1 | $0 | Sell |
15
-50
| -77% | -$794 | ﹤0.01% | 8535 |
|
|
2019
Q4 | $1K | Sell |
65
-638
| -91% | -$6.23K | ﹤0.01% | 7996 |
|
|
2019
Q3 | $7K | Sell |
703
-574
| -45% | -$6.38K | ﹤0.01% | 7361 |
|
|
2019
Q2 | $15K | Buy |
1,277
+706
| +124% | +$10.9K | ﹤0.01% | 6820 |
|
|
2019
Q1 | $10K | Buy |
571
+368
| +181% | +$6.11K | ﹤0.01% | 6833 |
|
|
2018
Q4 | $3K | Buy |
203
+138
| +212% | +$2.86K | ﹤0.01% | 7746 |
|
|
2018
Q3 | $1K | Sell |
65
-198
| -75% | -$4.5K | ﹤0.01% | 7866 |
|
|
2018
Q2 | $5K | Buy |
263
+93
| +55% | +$2.2K | ﹤0.01% | 7487 |
|
|
2018
Q1 | $3K | Buy |
170
+70
| +70% | +$2.02K | ﹤0.01% | 7455 |
|
|
2017
Q4 | $2K | Sell |
100
-483
| -83% | -$9.08K | ﹤0.01% | 7641 |
|
|
2017
Q3 | $10K | Buy |
583
+19
| +3% | +$317 | ﹤0.01% | 6903 |
|
|
2017
Q2 | $10K | Buy |
564
+156
| +38% | +$3.27K | ﹤0.01% | 6788 |
|
|
2017
Q1 | $10K | Buy |
408
+358
| +716% | +$8.16K | ﹤0.01% | 6625 |
|
|
2016
Q4 | $1K | Sell |
50
-81
| -62% | -$2.25K | ﹤0.01% | 7659 |
|
|
2016
Q3 | $5K | Sell |
131
-379
| -74% | -$15.4K | ﹤0.01% | 7142 |
|
|
2016
Q2 | $21K | Buy |
+510
| New | +$23.5K | ﹤0.01% | 6276 |
|
|
2016
Q1 | – | Sell |
-194
| Closed | -$10K | – | 8317 |
|
|
2015
Q4 | $10K | Buy |
+194
| New | +$9.79K | ﹤0.01% | 7295 |
|
|
2015
Q2 | – | Sell |
-91
| Closed | -$10K | – | 8923 |
|
|
2015
Q1 | $10K | Buy |
+91
| New | +$7.44K | ﹤0.01% | 7649 |
|
Other funds holding GENE
UBS Group's GENE Position: Q4 2024 in Review
UBS Group sold out of Genetic Technologies Ltd. (GENE) in Q4 2024, closing a stake of 8,866 shares — an estimated $6.87K sold.
UBS Group first reported a position in GENE in Q1 2015 and held it in 34 quarters. The position peaked at $21K in Q2 2016. 1 fund tracked by Wall St. Rank holds GENE as of Q4 2024.
- UBS Group reported no remaining Genetic Technologies Ltd. position as of Q4 2024 after selling out during the quarter.
- UBS Group sold 8,866 Genetic Technologies Ltd. shares in Q4 2024, an estimated $6.87K.
- UBS Group first reported a position in Genetic Technologies Ltd. in Q1 2015 and held it in 34 quarters.
- UBS Group's Genetic Technologies Ltd. position peaked at $21K in Q2 2016.
- 1 fund tracked by Wall St. Rank held Genetic Technologies Ltd. as of Q4 2024.
Based on UBS Group's 13F filing for Q4 2024, filed 14 Feb 2025.